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The role of new oral cephalosporins in 
rational antimicrobial therapy 
15331 In witm Activity of Oral Cephalosporins: 
A Comparative Review 
D. F e h g h a m .  GR Micro Lid, London, UK 
Chemical mocLfcations to the cephalosporin (cephem) nucleus have 
produced very many compounds of this class of antimicrobials 
which dSer in spectrum of antibacterial activity and pharmacoki- 
netic properties. A general classlfication of the compounds into first, 
second and third generation molecules largely reflects their stabil- 
ity to B-lactamase degradation and, hence, their improved activity 
against Gram negative species, particularly those of the Enterobac- 
teriaceae, with thlrd generation compounds genedy the most po- 
tent. Originally, the more active cephalosporins were available for 
parented adrmnistration, only However, during the last decade, a 
number of orally active third generation cephalosporins have be- 
come available either as pro-drugs (e.g. cefpodoxime and cefe- 
tamet) or those which are absorbed intact (e.g. cefixime, cefdbuten 
and cefdinir). For some of these molecules improved stability to 
p-lactamases has been gained at the expense of anti-Gram posi- 
tive activity (e.g. cefixime, ceftibuten, cefetamet) whilst some are 
characterised by stability to p-lactamases typical of h d  genera- 
tion compounds and retained activity against Gram positive species 
similar to second generation cephalosporins (e.g. cefdmir, cefpo- 
doxime). In this review, the activity of cefdinir, cefpodoxime, ce- 
fixime, ceftibuten and cefetamet (third generation cephalosporins) is 
compared with that of cefaclorAoracarbef, cefuroxime, and cefprozil 
(second generation cephalosporins) and cephaleldn (first generation 
cephalosporin) against a range of Gram positive and Gram negative 
bacterial pathogens causing infections in important therapeutic areas. 
Pharmacokinetic, Phannacodynamic, and Efficacy 
Considerations in Oral Cephalosporin Therapy 
Selection 
D.F! Nicolau. Harfford Hospital, Hartjord, C7; USA 
Over the last decade, much has been learned concerning the com- 
plex interaction of the host-drug-pathogen triad. Based on our cur- 
rent understanding of antimicrobial pharmacodynamics or the cor- 
relation of drug concentration and the clinical effect (e.g., bacterial 
killing) observed with the major classes of antimicrobials optimal 
administration techniques can be designed to maximize bactericidal 
activity. However, the clinician must remember that the administra- 
tion technique used to maximize antibacterial activity is very dif- 
ferent depending on drug class. The pharmacodynamic properties 
of a spechc antibiotic are therefore, an integration of two related 
areas, microbiologic activity and pharmacokmetics. According, it is 
not correct to choose antibiotics based solely on their microbiologic 
activity or pharmacokmetics, rather selection should based on their 
individual pharmacodynamic profiles. The application of these re- 
cent findings provides the opportunity to utilize antimicrobials in a 
manner which promotes maximal efficacy, while reducing the risk 
of drug toxicity. 
Extended Spectrum Cephalosporins in the 
Treatment of Acute Bacterial Sinusitis (ABS) 
J.M. Gwaltney, Jr. ', S .  Sawlainen', E? Rim3, P. Schenk4, 
W. Michael Scheld ', A. Sydnor ' , C. Keyserling ', A. Leigh ', 
KJ. Tack ' for the C e f h  Sinusitis Study Group. ' University .f 
Virginia Health Sciences Center, Department .f Internal Medicine, 
Charlottesville, VA, USA, 'Depart. of ORL, Central Military Hospital, 
Box 50, 00301 Hekinki, Finland, 'Provenra 50 1 Za, 08901 
L'Hospitalet de Llobregat, Barcelona, Spain, 4 U n i v ~ s i t y  Klinikfitr 
HNO-Krankheiten, Akerstrasse 4, A- 1090 Wen, Austria, 'Parke-Davis 
Pharmaceutical h e a r c h ,  2800 Plymouth Rd, Ann Arbor, MI ,  USA 
Cefdinir (CDR) is an extended-spectrum oral cephalosporin that 
is active against pathogens commonly seen in ABS, includmg S. 
pneumoniae, H. injuenzae, and M .  ratarrhalis. Two randomized, 
investigator blind, multicenter trials (one in the U.S., one in Europe) 
compared 2 doses of CDR (600 mg qd x 10 days and 300 mg 
bid x 10 days) to amoxicillin/clavulanate (A/C) (500 tid x 10 
days) in adult and adolescent patients with ABS. Twelve hundred 
twenty-nine patients entered the US. study, 698 with antral 
puncture; 569 patients entered the European study, all with antral 
puncture. Clinical response (cure or improvement) was determined 
7 to 14 days and 3-5 weeks post-therapy. Microbiologic eradication 
rates were determined 10 to 30 days post-therapy in a subset of 
patients with pre- and post-therapy sinus aspirate culture. Rates of 
adverse events were examined. CDR, given once or twice daily, was 
as effective chically (- 90% cure rate) as A/C given 3 times daily 
in the treatment of ABS. Microbiologic eradication rates were also 
similar in the 3 groups. CDR caused less adverse events requiring 
treatment discontinuation. 
Rational Oral Cephalasporin Use in the Clinical 
Practice Setting 
G.D. Campbell. USA 
No abstract available. 
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Serious Infection: Cutrent Challenges and Future 
Approaches 
R.G. Finch. University ofNottingham and T n e  C i t y  Hospital, 
Noffingham, NG5 IPB, UK 
The relationship between man and the microbd environment is 
delicately balanced. Despite more than half a century of antimi- 
crobd chemotherapy, infectious diseases remain a major problem, 
often changing in response to the expandmg elderly population, 
advances in medicine and other ecological pressures. Drug develop- 
ment has reached an impressive scale of sophistication; automated 
screening programmes, combinatorial chemisq and sophisticated 
structure-activity approaches have yielded new molecules, while new 
molecular targets are anticipated fiom gene mapping approaches. Mi- 
cro-organisms may m e r  less in their susceptibility than in their vir- 
ulence expression, which could be important at a time of increasing 
drug resistance. Serious lower respiratory tract infections in the hos- 
pitahsed patient - an important model for discussing these issues - is 
often currently managed with a broad spectrum cephalosporin, car- 
bapenem or quinolone. Predicting outcome is not solely a function 
of susceptibility but also needs to include considerations of pharma- 
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codynamic and virulence expression. Opportunities for combining 
convennonal approaches with biological response modification has 
been intensely hstrating and in part reflects our inabihty to cre- 
ate sensitive, reproducible and ckscriminatory human test models. 
However, the future approaches to the management of mfection re- 
main exciting and will clearly see progress on many hnts .  While 
chemotherapeutic intervention is likely to remain for the immediate 
future, opportunities for impacting of microbial virulence and host 
response are likely to emerge. 
(s381 Meta-analysis: A Useful Tool for Evaluating Data 
in Abdominal Infection 
J.S. Solomkin. University of C i M n m t i  College ofhfedicine, Cinn'nmti, 
Ohio, U S A  
Objective: To explore the utility of meta-analysis in in- 
tra-abdominal mfection. 
Methods: A meta-analysis of eight pre-marketing multicentre 
randomised clinical a d s  comparing treatment with meropenem 1 
g 8-hourly to over regimens, including imipenem/cilastatin, cefo- 
taxime plus metronidazole, and tobratnycin plus dindamycin. From 
1335 patients recruited into the studies, a total of 711 patients (355 
patients treated with meropenem and 356 with COmparatON) were 
both clinically and bacteriologically evaluable and included in the 
analysis. Logistic regression was used to demonstrate normality of 
the included data sets. 
Results: The overall clinical response rate was s& for the 
meropenem p u p  (336/355, 94.6%) and the comparator group 
(329/356, 92.4%). Response rates for the individual comparators 
were also similar. The overall odds ratio for treatment failure (es- 
timated from the odds ratios for all studies combined) was 0.76 
(95% confidence interval: 0.45, 1.26). A logistic regression analysis 
to identfy correlates of failure showed that length of hospital ad- 
mission, &se peritonitis and APACHE I1 score were sipficant 
contributors (overall model xz = 54.941, p < 0.0001). 
Conclusions: The data presented in this analysis support the opti- 
misation of carbapenem dosing for the treatment of intra-abdominal 
infection, and indicate that meropenem 1 g 8-hourly is as effec- 
tive as the standard comparators used in these mals. We believe that 
meta-analysis provides an important tool for examining clinical trials 
data in the area of intra-abdominal mfections. 
The Impact of Antibiotic Treatment on Endotoxin 
Release 
M.H. Miller. Albany Medical College, Albany, New Yo&, USA 
Recent in vitro and in yivo studies have explored the possibility that 
the extent and rate of bacterial eradication may not be the fac- 
tor whch best correlates with outcome in patients with selected 
Gram-negative infections. For B-lactams, a possible relationship has 
been proposed between PBP binding aEinity, relative endotoxin 
(LPS) release and outcome. In v i m  data suggest Werences in LPS 
release in E. coli and I? amginosa exposed to B-lactams with dif- 
ferent PBP &ty. However, the rate and extent of LPS release is 
concentration-dependent and best demonstrated using experimen- 
tal conditions whch may not be clitllcal relevant. Our studies with 
I? aeruginosa show a dissociation between LPS and murein release 
which, dong with morphological studies, suggest that both cell en- 
velope bruption and changes in biomass contribute to these dif- 
ferences. The potentla importance of dissmihities in LPS release 
is further confounded by the fact that aminoglycosides, often used 
in Combination with B-lacrams, show dose-dependent LPS bin- 
in vitro and decrease LPS effects in mice. W e  studies in rodents 
treated with fi-lactams also suggest that PBP bindmg correlates with 
LPS release and outcome, the doses used often result in pharmaco- 
dynamic profiles whch differ from those in man, and amino$yco- 
sides plus B-lactams significantly improve suMval when compared 
with monotherapy. Moreover, data in humans suggesting differences 
among B-lactams that relate to ditferences in PBP binding and en- 
dotoxin release are limited, and the clinical consequences are un- 
certain. Important factors in designing human stumes to determine 
the relevance of drug-induced LPS release include: in viho studies 
characterising the precise mechanisms of B-lactam-induced LPS re- 
lease and aminoglycoside binding; 4 outcome data using doses 
based upon pharmacodynamic principles; and careful consideration 
of comorbid conditions. Until such clinical data are available, antibi- 
otic choice should be based on eficacy rather than the theoretical 
consequences of LPS release. 
(s40( Differentiating Treatment Options for Serious 
Infections 
S.R. Norrby Department oflnfecous Disemer, Lund University 
Hospital, Land, Sweden 
During the last 15 years there has been a gradual change in the 
choice of antibiotics for the empirical treatment of life-threatening 
bacterial infections. The use of B-lactadaminoglycoside combina- 
tions has been replaced by third- generation cephalosporins with 
or without antibiotics with anti-anaerobic activity. Imipenem/cilas- 
tadn, the first carbapenem to be developed, has been the an- 
tibiotic of choice in some situations, particularly when anaerobic 
aetiology has been suspected. The fluoroquinolones have gained 
very h t e d  clinical use, often due to their poor activity against 
Gram-positive bacteria and against anaerobes. The sometimes in- 
discriminate use of third-generation cephalosporins has resulted in 
well-defined problems; namely, abundant resistance in Enterobaaer 
spp due to class I cephalosporinases and an increasing incidence of 
infections caused by members of the Enterobacteriaceae harbour- 
ing extended-spectrum B-lactamases. In addition, there are indica- 
tions that overuse of third-generation cephalosporins might favour 
the selection of Clostridium d@le, methicillin-resistant Stap~lococ- 
c i u  aureus and vancomycin-resistant enterococci. In the carbapenem 
group, imipenem/cilastatin has been joined by meropenem. The ad- 
vantages of meropenem over imipenem/cilastatin include: (i) better 
Gram-negative activity, particularly against Pseudomo~c ueruginosa, 
Haemophilus injuenzae, and the Enterobacteriaceae including hrm 
spp, Provider& spp and hforgunelh morganii; (ii) better solubhty al- 
lowing the use of intravenous bolus injections; (iii) a low incidence 
of nausea; and (iv) a low potentla for neurotoxicity, allowing the 
use of high doses and offering the possibility of using meropenem 
in patients win CNS infections. Meropenem therefore offers a novel 
option for the empirical therapy of Me-threatening infections, such 
as nosocomial pneumonia, and intra-abdominal, gynaecological and 
CNS infections. 
Evaluating the evidence: What are the current 
and future roles for aminoglycosides? 
Prevalence of local aminoglycoside resistance 
mechanisms and their impact on the 
management of infectious diseases 
G. Miller. Shering-Plough Research Institute, Kcnilworth, v, USA 
The prevalence of aminoglycoside resistance mechanisms in dif.- 
